Published in N Engl J Med on October 19, 2000
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
Inheritance of coronary artery disease in men: an analysis of the role of the Y chromosome. Lancet (2012) 5.16
Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet (2010) 4.46
Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J (2009) 1.77
Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol (2006) 1.72
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J (2012) 1.55
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke (2008) 1.52
The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov (2012) 1.39
Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J (2013) 1.31
Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res (2012) 1.28
Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis (2007) 1.25
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol (2008) 1.24
Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets. Hum Mol Genet (2008) 1.21
Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J (2011) 1.18
Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet (2008) 1.17
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis (2009) 1.11
Inflammatory markers of coronary risk. N Engl J Med (2000) 1.10
Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem (2008) 1.08
Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget (2011) 1.07
Transcriptional diversity during monocyte to macrophage differentiation. Immunol Lett (2008) 1.06
Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes (2010) 1.06
Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis. J Biol Chem (2008) 1.03
Inflammatory disturbances in preeclampsia: relationship between maternal and umbilical cord blood. J Pregnancy (2012) 1.02
Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol (2012) 1.01
Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med (2008) 1.01
The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients. J Vasc Surg (2007) 1.01
High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke (2009) 0.96
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Hum Genet (2010) 0.95
Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One (2011) 0.94
Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem (2012) 0.94
Linkage study of fibrinogen levels: the Strong Heart Family Study. BMC Med Genet (2008) 0.94
Disease risk factors identified through shared genetic architecture and electronic medical records. Sci Transl Med (2014) 0.94
Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis (2008) 0.93
Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II). Clin Res Cardiol (2007) 0.92
Assessing inflammatory status in cardiovascular disease. Heart (2007) 0.92
Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. Atherosclerosis (2013) 0.92
Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study. Atherosclerosis (2013) 0.91
Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem (2011) 0.89
To hydrolyze or not to hydrolyze: the dilemma of platelet-activating factor acetylhydrolase. J Lipid Res (2014) 0.89
Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. JACC Cardiovasc Imaging (2013) 0.89
Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. J Am Heart Assoc (2013) 0.89
Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. J Lipid Res (2009) 0.89
Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis. J Am Coll Cardiol (2012) 0.89
Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. Atherosclerosis (2015) 0.88
Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis (2008) 0.88
Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Transl Res (2011) 0.88
Age as a modulator of inflammatory cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2011) 0.88
Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis (2010) 0.88
Association of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke. PLoS One (2010) 0.88
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses (2012) 0.88
Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature. Tex Heart Inst J (2010) 0.88
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr (2010) 0.88
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications. World J Cardiol (2015) 0.87
Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2). Bioorg Med Chem Lett (2012) 0.87
Single nucleotide polymorphisms associated with coronary heart disease predict incident ischemic stroke in the atherosclerosis risk in communities study. Cerebrovasc Dis (2008) 0.87
Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiol Ther (2013) 0.86
HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS One (2013) 0.86
Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab (2010) 0.86
Preeclampsia is associated with compromised maternal synthesis of long-chain polyunsaturated fatty acids, leading to offspring deficiency. Hypertension (2012) 0.85
The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin (2011) 0.85
Macrophage VLDL receptor promotes PAFAH secretion in mother's milk and suppresses systemic inflammation in nursing neonates. Nat Commun (2012) 0.84
Lipid peroxidation generates biologically active phospholipids including oxidatively N-modified phospholipids. Chem Phys Lipids (2014) 0.84
The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr (2008) 0.84
Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag (2006) 0.83
Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Arthritis Res Ther (2007) 0.83
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine (2016) 0.82
Kidney function decline in the elderly: impact of lipoprotein-associated phospholipase A(2). Am J Nephrol (2011) 0.82
Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients. PLoS One (2012) 0.82
Prospective analysis of the association of infection with CagA bearing strains of Helicobacter pylori and coronary heart disease. Heart (2002) 0.82
Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria. Diab Vasc Dis Res (2009) 0.81
Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail (2009) 0.81
Circulating and PBMC Lp-PLA2 associate differently with oxidative stress and subclinical inflammation in nonobese women (menopausal status). PLoS One (2012) 0.81
Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients. Exp Mol Med (2009) 0.81
Novel markers of peripheral arterial disease. Vasc Med (2009) 0.81
Lesions and lipids and radicals--O my! Tex Heart Inst J (2004) 0.81
Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol (2007) 0.80
Taiwanese female vegetarians have lower lipoprotein-associated phospholipase A2 compared with omnivores. Yonsei Med J (2011) 0.80
Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study. Atherosclerosis (2014) 0.80
Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection. HIV Med (2014) 0.80
The association among lipoprotein-associated phospholipase A2 levels, total antioxidant capacity and arousal in male patients with OSA. Int J Med Sci (2011) 0.80
Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults. Am J Hematol (2008) 0.79
Racial variation in lipoprotein-associated phospholipase A₂ in older adults. BMC Cardiovasc Disord (2011) 0.79
Usefulness of self-reported periodontal disease to identify individuals with elevated inflammatory markers at risk of cardiovascular disease. Am J Cardiol (2008) 0.79
Alteration in lipoprotein-associated phospholipase A2 levels during acute coronary syndrome and its relationship to standard biomarkers. Lipids Health Dis (2012) 0.78
Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. Lipids Health Dis (2014) 0.78
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res (2009) 0.78
Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation (2008) 0.78
Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Biochem J (2001) 0.78
High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. J Am Coll Cardiol (2016) 0.78
The NF-κB pathway: regulation of the instability of atherosclerotic plaques activated by Fg, Fb, and FDPs. Mol Cell Biochem (2013) 0.77
Association of lipoprotein-associated phospholipase A₂ with characteristics of vulnerable coronary atherosclerotic plaques. Yonsei Med J (2011) 0.77
Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients. PLoS One (2015) 0.77
Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis (2008) 0.77
Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways. Biol Open (2015) 0.77
Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X. Heart Vessels (2013) 0.76
Biomarkers and their involvement in the early diagnosis of right ventricular dysfunction in type 2 Diabetes Mellitus. J Med Life (2012) 0.76
Differential expression of platelet-activating factor acetylhydrolase in lung macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 0.76
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Biochemical detection of left-ventricular systolic dysfunction. Lancet (1998) 7.51
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Antithrombotic treatment and atrial fibrillation. BMJ (1992) 5.33
Randomised controlled trial of specialist nurse intervention in heart failure. BMJ (2001) 4.43
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
Effect of socioeconomic deprivation on waiting time for cardiac surgery: retrospective cohort study. BMJ (2000) 4.21
Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 4.01
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet (1997) 3.70
Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. Circulation (2002) 3.63
Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation (2001) 3.57
Nonparametric analysis of statistic images from functional mapping experiments. J Cereb Blood Flow Metab (1996) 3.44
Diffuse axonal injury in head injury: definition, diagnosis and grading. Histopathology (1989) 3.24
Longer booking intervals in general practice: effects on doctors' stress and arousal. Br J Gen Pract (1991) 3.21
Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke (1999) 2.89
Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia (2006) 2.88
Effect of reducing ambulance response times on deaths from out of hospital cardiac arrest: cohort study. BMJ (2001) 2.85
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J (1985) 2.74
von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J (2002) 2.66
Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol (2003) 2.63
Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ (1996) 2.51
Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet (2004) 2.51
ACE inhibitor use is associated with hospitalization for severe hypoglycemia in patients with diabetes. DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside, Scotland. Medicines Monitoring Unit. Diabetes Care (1997) 2.46
The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ (1997) 2.44
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol (1990) 2.43
Health promotion in the general practice consultation: a minute makes a difference. BMJ (1992) 2.35
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation (1996) 2.32
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol (1999) 2.18
Severe hypotension after first dose of enalapril in heart failure. Br Med J (Clin Res Ed) (1985) 2.14
Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J (1999) 2.08
Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J (2000) 2.08
Acute exercise and markers of endothelial injury in peripheral arterial disease. Eur J Vasc Endovasc Surg (1997) 2.07
Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia (2011) 2.06
The use of the dermatoscope to identify early melanoma using the three-colour test. Br J Dermatol (2002) 2.06
Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med (2008) 2.06
Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut (1997) 1.98
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol (2001) 1.96
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J (1999) 1.92
Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol (1998) 1.88
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ (1996) 1.85
The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J (2004) 1.84
Socioeconomic deprivation and NHS orthodontic treatment delivery in Scotland. Br Dent J (2012) 1.84
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure. Am J Med (1984) 1.83
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol (2001) 1.83
Vitamin B(1) status assessed by direct measurement of thiamin pyrophosphate in erythrocytes or whole blood by HPLC: comparison with erythrocyte transketolase activation assay. Clin Chem (2000) 1.82
Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart (2001) 1.77
Ischaemic brain damage is still common in fatal non-missile head injury. J Neurol Neurosurg Psychiatry (1989) 1.75
Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol (1997) 1.72
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1999) 1.71
Estimating urinary albumin excretion rate of diabetic patients in clinical practice. BMJ (1993) 1.70
A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease. J Thromb Haemost (2007) 1.69
Mortality in heart failure: clinical variables of prognostic value. Br Heart J (1987) 1.67
Socioeconomic factors associated with risk of upper aerodigestive tract cancer in Europe. Eur J Cancer (2009) 1.66
Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1986) 1.64
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J (2002) 1.61
Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest. BMJ (1996) 1.60
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J (1993) 1.60
Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol (1991) 1.59
Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J (1996) 1.59
Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis (2000) 1.58
M1 protein and protein H: IgGFc- and albumin-binding streptococcal surface proteins encoded by adjacent genes. Biochem J (1994) 1.55
Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol (2013) 1.55
The cytotoxicity of nitroxyl: possible implications for the pathophysiological role of NO. Arch Biochem Biophys (1998) 1.49
Oesophageal eosinophilic infiltration in patients with noncardiac chest pain. Aliment Pharmacol Ther (2011) 1.49
Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun (1996) 1.48
Insulin resistance, haemostatic and inflammatory markers and coronary heart disease risk factors in Type 2 diabetic men with and without coronary heart disease. Diabetologia (2004) 1.46
International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study. Eur Heart J (1999) 1.46
Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care (1989) 1.45
Biological properties of a Streptococcus pyogenes mutant generated by Tn916 insertion in mga. Microb Pathog (1995) 1.45
Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet (1993) 1.45
The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem (2001) 1.44
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax (2005) 1.44
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes. Diabetes Res Clin Pract (2011) 1.44
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost (2007) 1.43
myo-inositol metabolites as cellular signals. Eur J Biochem (1990) 1.42
Relation between extent of coronary artery disease and blood viscosity. Br Med J (1980) 1.42
Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. Clin Chem (1988) 1.42
Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort. Atherosclerosis (1999) 1.41